Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0974-2026

Brand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral Nails Recall

Brand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral Nails Model/Catalog Number: 815609300 Software Version: N/A Product Description: Affixus 9 mm, Length 300 mm, Left, Trochanteric Nail Component: N/A

FDA recall Class II

Ongoing

FDA lists this Class II recall for Brand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral Nails. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0974-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Dec 2, 2025
FDA report date
Dec 31, 2025
Quantity in commerce
11
Distribution
See key details
FDA cause
Process design

What is being recalled?

Brand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral Nails Model/Catalog Number: 815609300 Software Version: N/A Product Description: Affixus 9 mm, Length 300 mm, Left, Trochanteric Nail Component: N/A

Affected model & UDI checker

Search the exact identifiers published for Z-0974-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
815609300Brand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral NailsCheck source noticeNot specified
Not specifiedBrand Name: Affixus Antegrade Femoral Nailing System Product Name: Affixus Antegrade Femoral NailsCheck source notice00887868144462
FDA code information

Lot Code: Model No 815609300 ; UDI-DI (01)00887868144462(17)340826(10)66717600 ; Lot Number 66717600

View the original FDA recall notice

Why was this product recalled?

Affected implants may have undersized distal diameter along length of the shaft, which could lead to implant fatigue fracture. Potential health risk if implant fatigue fracture occurs include adverse local tissue reaction, pain or ache, non-union or malunion, or tissue damage necessitating surgical intervention.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Zimmer, Inc. take?

Firm began notifying customers on December 2, 2025 via Urgent Medical Device Recall letters. Distributors are to locate and quarantine affected product in their inventory. They must also return all affected product from their distributorship and from affected hospitals within their territory. Risk Managers are to assist Zimmer Biomet sales representatives in quarantining all affected product. Sales representatives will remove the product from customer facilities. Surgeons are to maintain awareness of the issue, but there are no patient-monitoring instructions related to this recall recommended beyond their existing follow-up schedules.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology